NovoCure (NVCR) Capital Expenditures Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 10.17% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 1.81% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2.15% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.35% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 8.08% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -5.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.41% |
| Dec 31, 2025 | -8.69% |
| Sep 30, 2025 | -0.28% |
| Jun 30, 2025 | 9.92% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | -14.43% |
| Sep 30, 2024 | 47.98% |
| Jun 30, 2024 | 63.52% |
| Mar 31, 2024 | 43.58% |
| Dec 31, 2023 | 5.80% |
| Sep 30, 2023 | 37.63% |
| Jun 30, 2023 | 27.87% |
| Mar 31, 2023 | 25.07% |
| Dec 31, 2022 | 28.16% |
| Sep 30, 2022 | 28.18% |
| Jun 30, 2022 | 19.89% |
| Mar 31, 2022 | 29.87% |
| Dec 31, 2021 | 99.67% |
| Sep 30, 2021 | 34.57% |
| Jun 30, 2021 | 45.27% |
| Mar 31, 2021 | 75.46% |
| Dec 31, 2020 | 2.07% |
| Sep 30, 2020 | 72.29% |
| Jun 30, 2020 | 106.58% |
| Mar 31, 2020 | 44.52% |
| Dec 31, 2019 | 70.35% |
| Sep 30, 2019 | 16.45% |
| Jun 30, 2019 | 0.83% |
| Mar 31, 2019 | 32.39% |
| Dec 31, 2018 | 19.37% |
| Sep 30, 2018 | 4.20% |
| Jun 30, 2018 | -22.12% |
| Mar 31, 2018 | 6.57% |
| Dec 31, 2017 | 137.15% |